| Project/Area Number |
16K10102
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Embryonic/Neonatal medicine
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高橋 幸博 奈良県立医科大学, 医学部, 研究員 (60142379)
|
|---|
| Project Period (FY) |
2016-10-21 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | Thrombopas / HemosilTMThrombopas / 新生児DIC / プロテインC |
|---|
| Outline of Final Research Achievements |
We compared the PICI% of newborns to infants, thrombin generation, thrombin generation after using Protac, and normal adults. In the newborn, anticoagulation and coagulation are well balanced due to immaturity of the PC/PS control system and decreased physiological production of coagulation factors. If the anticoagulant ability declines due to infection or asphyxia, DIC can easily occur, so it may be necessary to consider the necessity of PC, PS or FFP administration.
When the PC activity reaches 50%, the PICI% approaches 80%, and when the PC activity reaches 70%, the PICI% rises to the normal level, and there is no significant change after FFP administration. Therefore, it was expected that the anticoagulant ability would be maintained if the PC activity was 50% or more.
|
| Academic Significance and Societal Importance of the Research Achievements |
新生児や乳児では、仮死や重症感染症となったときに、血液凝固能と血液抗凝固能のバランスが崩れやすく、播種性血管内凝固症候群を容易に引き起こしてしまう。そのため、新生児や乳児では、病初期からプロテインCやプロテインS、新鮮凍結血漿の投与が有効である。
|
